MitoBurn (L-BAIBA).
The exercise-in-a-pill molecule. Your muscles release it naturally during training. Supplies L-BAIBA, the small amino acid your muscles release when you train. It's studied for body composition and metabolic signalling rather than for anything you would feel.
Reviewed March 2026
- Category
- Compound
- Also filed under
- Fat browningExercise mimeticMetabolism
What MitoBurn (L-BAIBA) is, and what it does.
- Does it work
- Suits people in a training block or eating in a deficit who want a stimulant-free addition. Human research is early, so the metabolic angle is promising rather than settled.
- How much to take
- Start with 250 to 500mg a day of the valine-derived form. That band is the everyday amount, and the 1,000mg used in research is a study condition rather than a target.
- Time to feel it
- There's no acute effect to time. Human work is early, so what changes gets read over weeks on body composition and metabolic markers rather than through sensation.
- The first dose
- Day one is uneventful. It's a small amino acid your body already makes from valine, absorbed within an hour or two, with no stimulant edge to it.
- With regular use
- Weeks to months is the timescale. What gets read is body composition and metabolic markers, because human research is early and there's no acute sensation to track.
- How well tolerated
- Well tolerated in the research so far, and it's a molecule your body already makes from valine. Long-term human data is thin, so anyone pregnant or on medication should ask a clinician.
- How it feels
- Subtle warmth maybe. Not a stimulant. Works internally.
- The overlooked benefit
- Your own production of it runs through valine breakdown, a pathway that needs B6, riboflavin, thiamine, biotin and B12 at successive steps, so B vitamin status sits underneath it.
250 to 500mg a day is where MitoBurn (L-BAIBA) works.
Source: Roberts et al., Cell Metabolism, 2014; NNB Nutrition product literature
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
MitoBurn (L-BAIBA) has emerging evidence. Based on 99+ studies.
- Rise in plasma beta-aminoisobutyric acid after exerciseCohort study
- Browning of white adipose tissueAnimal study
- Fatty acid oxidation signalling in muscle and liverAnimal study
- Body composition in resistance-trained adultsRandomised trial
Questions people ask about MitoBurn (L-BAIBA).
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- People who've already covered the basics (diet, sleep, exercise) and want to fine-tune. It's not essential, but could be worthwhile for the right person.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Beta-aminoisobutyric acid is a downstream product of valine catabolism through methylmalonate semialdehyde. Valine supply is the amino acid route the body uses to form it.
The branched chain pool carries the valine that feeds the catabolic route ending in beta-aminoisobutyric acid. Branched chain aminotransferase and the dehydrogenase complex handle both.
Beta-aminoisobutyric acid signals toward fatty acid oxidation in muscle and liver, and carnitine carries long chain fatty acids into the mitochondrion for that oxidation. The signal and the transport step sit on the same route.
Branched-chain aminotransferase requires pyridoxal 5-phosphate to move the amino group off valine in the first committed step of valine catabolism, the pathway that produces beta-aminoisobutyric acid endogenously. Without adequate B6 that step slows. This is textbook cofactor dependence for the pathway that makes BAIBA in the body, not a claim about supplemented BAIBA.
FAD, made from riboflavin, is the prosthetic group of the acyl-CoA dehydrogenases that carry branched-chain and fatty acyl intermediates through their oxidation steps. Valine catabolism and fatty acid beta-oxidation both run on these enzymes. Riboflavin status therefore sits upstream of the same mitochondrial machinery a BAIBA product is positioned around.
Propionyl-CoA carboxylase and 3-methylcrotonyl-CoA carboxylase are biotin-dependent enzymes in branched-chain amino acid catabolism, and biotin is covalently attached to each by holocarboxylase synthetase. Valine flux through to succinyl-CoA runs through a biotin-dependent step. The cofactor relationship is settled and needs no trial to state.
Methylmalonyl-CoA mutase uses adenosylcobalamin to convert methylmalonyl-CoA to succinyl-CoA, the final step that feeds valine carbon into the TCA cycle. Low B12 backs this step up and raises methylmalonic acid. Any formula built around valine-pathway metabolites sits downstream of this requirement.
Leucine, isoleucine and valine share the LAT1 large neutral amino acid transporter and the same branched-chain aminotransferase and dehydrogenase complex. Loading one branched-chain amino acid heavily shifts uptake and catabolic flux away from the others. In a product carrying both leucine and a valine-derived metabolite, the competition is at the transporter and at the shared enzyme, and it runs in both directions.
HMB is a downstream metabolite of leucine, as BAIBA is of valine, so both are branded end-products of branched-chain amino acid catabolism sold as their own ingredients. They are formulated together in body-composition products on that shared logic. The two occupy different branches of the pathway and no combination measurement has been published.
Nicotinamide riboside is converted to NAD+, the electron acceptor every dehydrogenase in fatty acid oxidation and the TCA cycle depends on. BAIBA products are positioned around mitochondrial fuel handling, which is exactly where the NAD+ pool is rate-relevant. The NAD+ chemistry is settled; the pairing itself has not been tested together.
Coenzyme Q10 accepts electrons from complex I, complex II and from electron transfer flavoprotein dehydrogenase, the entry point for fatty acid oxidation, and passes them to complex III. Any ingredient positioned around mitochondrial substrate oxidation depends on an intact quinone pool downstream. This is respiratory chain biochemistry, not an interaction claim.
Lipoic acid is the covalently bound cofactor on the E2 subunit of the branched-chain alpha-ketoacid dehydrogenase complex, the same architecture used by pyruvate dehydrogenase. That complex performs the irreversible oxidative decarboxylation step in valine catabolism. The cofactor role is structural and established, distinct from lipoic acid's separate redox behaviour as a supplement.
Caffeine antagonises adenosine receptors and raises circulating catecholamines, which increases lipolysis and fatty acid availability. It is the most common co-ingredient in products carrying BAIBA. The two mechanisms are independent, and the stimulant load in the finished product comes entirely from the caffeine.
Creatine expands the phosphocreatine pool that buffers ATP during brief maximal effort, an effect with a deep human literature. BAIBA is positioned around oxidative substrate handling, a different energy system. Products combine them to cover both, which is a formulation rationale rather than a measured interaction.
Every reaction that binds or transfers ATP does so with ATP chelated to magnesium, which makes the mineral a requirement across the kinases and synthetases of energy metabolism. Amino-acid metabolite products are formulated with it on that basis. The requirement is textbook and does not depend on the metabolite.
Glutamine carries amino nitrogen between tissues and accepts the amino groups released by branched-chain aminotransferase in muscle. High branched-chain amino acid flux raises muscle glutamine turnover. The nitrogen relationship is established physiology; whether adding glutamine changes anything about a BAIBA product has not been shown.
Nothing specific on file for MitoBurn (L-BAIBA). Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What MitoBurn (L-BAIBA) actually does.
Beta-aminoisobutyric acid is a small non-protein amino acid produced endogenously from two routes: catabolism of the branched-chain amino acid valine, which yields the L enantiomer, and catabolism of the pyrimidine base thymine, which yields the D enantiomer.
MitoBurn is a branded ingredient supplying L-beta-aminoisobutyric acid, the valine-derived enantiomer, rather than the racemic mixture; the two enantiomers arise from different metabolic origins and are not interchangeable descriptions.
BAIBA appears in plasma at higher concentrations after exercise, which is why it is described as an exercise-associated small molecule; an association between a metabolite and an activity does not establish that supplementing the metabolite reproduces the activity.
Valine catabolism to BAIBA runs through branched-chain aminotransferase, then the branched-chain alpha-ketoacid dehydrogenase complex, and depends on vitamin B6, lipoic acid, thiamine, riboflavin, biotin and vitamin B12 at successive steps.
Where MitoBurn (L-BAIBA) comes from.
It is made in a chemical plant, not extracted from a food. The molecule is the same one your body makes when it breaks down the amino acid valine, and the branded version is specifically the mirror-image form that matches that route. It is crystallised, dried and tested before it goes into powders.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Beta-aminoisobutyric acid is built by chemical synthesis from simple organic precursors rather than isolated from a biological source. Suppliers do not generally disclose the specific starting materials.
The three-carbon backbone bearing an amino group at the beta position and a methyl branch is assembled by standard organic synthesis. The endogenous route in the body, valine or thymine catabolism, is not how the ingredient is made.
To supply the L enantiomer rather than the racemate, the material is either resolved from a racemic mixture or made by an asymmetric route. This step is what a branded L-BAIBA specification turns on.
The amino acid is crystallised, washed and dried. Residual solvent, heavy metal and identity testing are the usual release specifications.
Batches are assayed for total content and, for single-enantiomer material, for enantiomeric excess by chiral chromatography. A certificate stating only total BAIBA does not confirm which enantiomer is in the drum.
MitoBurn is a branded L-BAIBA supplied by NNB Nutrition and blended into finished powders and capsules by other manufacturers. The brand name identifies the supplier specification, not a different molecule.
Getting MitoBurn (L-BAIBA) from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- Randomised supplementation trial of L-BAIBA, given with and without grains of paradise, measuring changes in resting metabolic rate and body composition in adults.Randomised trial. Allen et al., 2026 (Nutrition Journal). PMID 42271377 ↗
These are the studies our verdict leans on, chosen from the 1 we read for MitoBurn (L-BAIBA). The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.